93864-26-7

Basic information

• Product Name: 3-[4-(4-methoxyphenyl)-piperazin-1-yl]-propionitrile
• Synonyms: 3-[4-(4-methoxyphenyl)-piperazin-1-yl]-propionitrile
• CAS NO: 93864-26-7
• Molecular Weight: 245.324
• Mol File: 93864-26-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-[4-(4-methoxyphenyl)-piperazin-1-yl]-propionitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-(4-methoxyphenyl)-piperazin-1-yl]-propionitrile(93864-26-7)
• EPA Substance Registry System: 3-[4-(4-methoxyphenyl)-piperazin-1-yl]-propionitrile(93864-26-7)

Safety Data

• Hazardous Substances Data: 93864-26-7(Hazardous Substances Data)

Upstream product

• 38212-30-5 4-(4-methoxyphenyl)piperazine 
• 107-13-1 acrylonitrile 
• 104-94-9 4-methoxy-aniline 

Downstream Products

• 129011-07-0 2-Methoxy-N-{3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl}-5-sulfamoyl-benzamide 
• 40255-50-3 3-(4-(4-methoxyphenyl)piperazin-1-yl)propan-1-amine 
• 740831-36-1 1-(4-methoxyphenyl)-4-[2-(1H-tetrazol-5-yl)-ethyl]-piperazine 

Relevant articles and documents

Synthesis of Kappa Opioid Antagonists Based on Pyrrolo[1,2-α]quinoxalinones Using an N-Arylation/Condensation/Oxidation Reaction Sequence

The quinoxaline and quinoxalinone family of nitrogen heterocycles is present in molecules of therapeutic relevance for diverse applications ranging from infectious diseases to neuroscience targets. Here, we describe a general synthetic sequence to afford pyrrolo[1,2-α]quinoxalinones from commercially available starting materials and their use in preparing potential kappa opioid receptor antagonists. The biological data obtained from the latter set of compounds is briefly presented and discussed.

Optically active antifungal azoles: Synthesis and antifungal activity of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-{2-[4-aryl-piperazin-1-yl]-ethyl} -tetrazol-2-yl/1-yl)-1-[1,2,4]-triazol-1-yl-butan-2-ol

A series of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-{2-[4-aryl-piperazin-1-yl]- ethyl}-tetrazol-2-yl)-1-[1,2,4]-triazol-1-yl-butan-2-ol (11a-n) and (2R,3S)-2-(2,4-difluorophenyl)-3-(5-{2-[4-aryl-piperazin-1-yl]-ethyl} -tetrazole-1-yl)-1-[1,2,4]-triazol-1-yl-butan-2-ol (12a-n) has been synthesized. The antifungal activity of compounds was evaluated by in vitro agar diffusion and broth dilution assay. Compounds 11d and its positional isomer 12d having 3-trifluoromethyl substitution on the phenyl ring of piperazine demonstrated significant antifungal activity against variety of fungal cultures (Candida spp. C. neoformans and Aspergillus spp.). The compound 12d showed MIC value of 0.12μg/mL for C. albicans, C. albicans V-01-191A-261 (resistant strain); 0.25μg/mL for C. tropicalis, C. parapsilosis ATCC 22019 and C. krusei and MIC value of 0.5μg/mL for C. glabrata, C. krusei ATCC 6258, which is comparable to itraconazole and better than fluconazole. Further, compound 11d showed significant activity (MIC; 0.25-0.5μg/mL) against Candida spp. and strong anticryptococcal activity (MIC; 0.25μg/mL) against C. neoformans.